Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predicting Response and Exposure Changes in Cirrhosis for Effectiveness
NCT07750587Not yet recruiting
- Sponsor
- University of Amsterdam
- Start
- Nov 2026
- Primary completion
- Nov 2028
01
Overview
Open-label, single-arm trial of caffeine, warfarin, esomeprazole, metoprolol and midazolam, sponsored by University of Amsterdam. Primary endpoints: Unbound clearance at 24 months and Area under the plasma concentration versus time curve at 24 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
caffeinewarfarinesomeprazolemetoprololmidazolam
Beyond the preview
Go deeper on NCT07750587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07750587.